Heron Therapeutics gains approval for new pain relief therapy but faces low revenues

Heron Therapeutics has received approval for a new therapy that has significant market potential. However, the company is currently experiencing low revenue levels despite this approval. The therapy aims to provide opioid-free pain relief for surgical patients. This development marks a shift in Heron's product offerings, which previously faced challenges in generating substantial income. Despite the promising approval, Heron continues to struggle with financial performance. The company’s future revenue growth remains uncertain as it works to capitalize on its new therapy.